Teri Toth
Keine laufenden Positionen mehr
Profil
Teri Toth worked as a Quality Director at MaxCyte, Inc., Director-Quality Systems at Cylex, Inc., Principal at Qiagen, Inc., and Principal at Dexall Biomedical Labs, Inc. She obtained an undergraduate degree from Bridgewater College.
Ehemalige bekannte Positionen von Teri Toth
| Unternehmen | Position | Ende |
|---|---|---|
Cylex, Inc.
 Cylex, Inc. Medical SpecialtiesHealth Technology Cylex is a privately held global life science company that is in the development and manufacture of in vitrodiagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides a platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD and was founded in 1992 | Corporate Officer/Principal | 18.11.2013 |
| Dexall Biomedical Labs, Inc. | Corporate Officer/Principal | - |
| MAXCYTE, INC. | Corporate Officer/Principal | - |
Qiagen, Inc.
 Qiagen, Inc. Miscellaneous Commercial ServicesCommercial Services Qiagen, Inc. provided technologies for separating, purifying and handling nucleic acids. The company was founded in 1988 and was headquartered in Germantown, MD. | Corporate Officer/Principal | - |
Ausbildung von Teri Toth
| Bridgewater College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MAXCYTE, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Cylex, Inc.
Cylex, Inc. Medical SpecialtiesHealth Technology Cylex is a privately held global life science company that is in the development and manufacture of in vitrodiagnostic products. ImmuKnow is the in vitro diagnostic utilized to detect cell-mediated immunity (CMI) in an immunosuppressed population and is increasingly being adopted at organ transplant centers throughout the United States and abroad. The Company's patented technology provides a platform allowing clinical researchers to simply and reproducibly measure CMI for the development of new diagnostics, biomarkers and companion assays. The company is based in Columbia, MD and was founded in 1992 | Health Technology |
Qiagen, Inc.
Qiagen, Inc. Miscellaneous Commercial ServicesCommercial Services Qiagen, Inc. provided technologies for separating, purifying and handling nucleic acids. The company was founded in 1988 and was headquartered in Germantown, MD. | Commercial Services |
| Dexall Biomedical Labs, Inc. |
